Takeda To Help Develop Lundbeck’s First-In-Class Mood Disorder Candidates In Japan, U.S.

Deal includes $40 million upfront payment and potential $345 million in milestones for Lundbeck.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

More from Asia